Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has submitted a marketing authorization application to the European Medicines Agency for pazopanib as an oral therapy for patients with advanced or metastatic renal cell carcinoma.
Subscribe to our email newsletter
The marketing authorization application (MAA) submission is based on positive results from a randomized, double-blind, placebo-controlled Phase III study of pazopanib in treatment-naïve and cytokine-pre-treated patients with advanced renal cell carcinoma (RCC).
In December 2008, GlaxoSmithKline (GSK) also completed the submission of a new drug application to the FDA for pazopanib as an oral therapy for patients with advanced RCC. The filing is currently under regulatory review.
Paolo Paoletti, senior vice president of R&D oncology unit at GSK, said: “If approved, pazopanib will offer physicians and patients a new therapeutic option for advanced kidney cancer and demonstrate our ongoing commitment to the development of innovative and personalized treatments for patients with cancer.”